Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years

Japanese drug makers and regulatory authorities have been unable to conduct onsite inspections of overseas manufacturing facilities for two years now due to the COVID-19 pandemic. To compensate, they have tried a number of makeshifts, such as remote check-ups. Jiho...read more